Eyepoint Pharmaceuticals announced that its Phase 3 clinical trial of Duravyu, an experimental therapy for wet age-related macular degeneration (wet AMD), fell short of its primary objective. According to the source, patients who received Duravyu with a less-frequent injection regimen did not maintain vision compared with a standard treatment, meaning the study did not meet the trial’s primary endpoint.
The company described the result as a clinical setback. The source reports that the failed primary endpoint directly endangers Eyepoint’s plan to pursue regulatory approval for Duravyu. The accessible portion of the source did not include detailed numerical efficacy results, statistical analyses, or specific endpoint definitions.
The reported Phase 3 failure had immediate commercial consequences. Eyepoint’s stock price declined sharply after the announcement, reflecting investor concern about the drug’s approval prospects and the commercial viability of a product positioned as requiring fewer intravitreal injections.
The article indicates that the trial setback could influence Eyepoint’s regulatory timeline and its standing in a competitive market for longer-acting treatments for wet AMD.
The source notes that shares of Ocular Therapeutix, a maker of a competing eye treatment, rose following Eyepoint’s announcement. Ocular’s rival therapy is expected to be submitted to the U.S. Food and Drug Administration later in the year, according to the source. Both companies are pursuing therapies intended to maintain vision in people with wet AMD while reducing injection frequency compared with currently approved options.
This broader competitive context — multiple companies developing longer-acting intravitreal treatments for wet AMD — was emphasized in the source as a factor that heightens the commercial and regulatory stakes of Eyepoint’s trial outcome.
Because Duravyu did not achieve its primary endpoint in the Phase 3 study, Eyepoint’s plans to seek regulatory approval are described in the source as imperiled. The accessible report framed the result as potentially jeopardizing the company’s ability to position Duravyu as a less-frequently dosed alternative to existing therapies for wet AMD.
The source did not provide further information about Eyepoint’s next steps, such as whether the company will pursue additional analyses, request regulatory discussions, modify dosing strategies, conduct supplemental studies, or change submission timing. Those details were not reported in the portion of the article available without a STAT+ subscription.
The source summary and paywalled article highlighted the key outcome but did not include several specific trial elements in the publicly accessible portion. The following were not reported in the available text:
Because these important trial details were not included in the accessible excerpt, clinicians and stakeholders seeking a full evaluation of the clinical data and its implications will need to consult the complete STAT+ story or company communications and regulatory filings for the comprehensive dataset and any subsequent company commentary.
The source article was written by Adam Feuerstein and published Aug. 17, 2026. The item was identified as a STAT+ exclusive, with additional content behind the publication’s paywall. The publicly available portion provided the principal takeaways: a Phase 3 primary endpoint miss for Duravyu in wet AMD, market reactions, and the competitive positioning relative to Ocular Therapeutix.
Clinicians, regulators, and investors should seek the full trial data and Eyepoint’s formal disclosures to assess the magnitude and clinical relevance of the trial result, including safety signals and any subgroup or secondary endpoint findings that might influence future development or regulatory strategy.